Cutaneous T-Cell Lymphoma (CTCL)

Overview of Mycosis Fungoides and related conditions.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
DermatologyOncologyHaematology

Clinical Guidelines

Mogamulizumab for treating cutaneous T-cell lymphoma: Final scope (NICE)
National
NICE guideline TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
National
NICE guideline TA720: Recommendations for cutaneous T-cell lymphoma
National
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines
National
ASTCT and USCLC clinical practice recommendations for mycosis fungoides and Sézary syndrome
Local
ASTCT and USCLC Clinical Practice Recommendations for Mycosis Fungoides and Sézary Syndrome
Local
ASTCT and USCLC Clinical Practice Recommendations for Mycosis Fungoides and Sézary Syndrome
Local
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome after at least one prior systemic therapy
Local
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome after at least one prior systemic therapy
Local
Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium
Local
Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium
Local
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Primary Cutaneous Lymphomas
Local
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Local
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Local